Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clenia Plus Topical Cleanser is a prescription dermatological preparation containing sodium sulfacetamide 9% and sulfur 4.25% in a suspension vehicle. Marketed by Allegis Pharmaceutical, it is indicated for the topical control of acne vulgaris, acne rosacea, and seborrheic dermatitis. Sodium sulfacetamide is a sulfonamide with antibacterial activity against susceptible strains of bacteria, acting as a competitive antagonist of para-aminobenzoic acid (PABA), which is essential for bacterial folic acid synthesis. Sulfur provides keratolytic action, helping to soften and shed the outer layer of the skin, and possesses mild antifungal and antibacterial properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium sulfacetamide + sulfur.